Liver Disease Diagnostics Market Size, Share, By Diagnostic Technique (Imaging [Electrography, Ultrasound, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scanner, and Others), Blood Test [(Fragment Omics, Liver Function Test, Antibody Test, and Others), Genetic Test], Disease Type (Hepatitis, Fatty Liver Disease, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Alcoholic Fatty Liver Disease, and Others), End-user (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

• The target market is expected to increase at a rate of USD 9.4 Billion by 2035
• Liver disease diagnostics market size was valued at USD 5.5 Billion in 2024.
• The market is expanding at a CAGR of 5.5%.

Liver disease diagnostics involves a combination of blood test, imaging tests, and tissue samples. These tests help to determine cause and survival of liver damage and guide to make treatment decisions. Liver disease diagnostics can be used to assess the health of the liver and identify any abnormalities, and diseases, which affects the liver. The increasing prevalence of liver disease and rising demand for development of more accurate and rapid diagnostic test, help to drive liver disease diagnostic market growth.

Impact of AI on Liver Disease Diagnostics Market:

Artificial intelligence (AI) significantly impacts the liver disease diagnostics market by improving liver disease diagnostics through more accurate and efficient detection for liver fibrosis, liver cancer tumors and predicts disease progression. AI algorithms can analyze medical imaging data, allowing for early detection with high accuracy data. AI models can analyze patient data to predict progression of liver disease, potential treatment response and overall survival of patient.

Key Drivers of Target Market:

Increasing Prevalence of Liver Disease Boost the Market Opportunity

The increasing prevalence of liver diseases, such as hepatitis and fatty liver disease, created demand for efficient diagnostics solutions. The rising awareness of early detection and treatment of liver conditions is expanding demand for advanced diagnostic tools. Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis, liver cirrhosis, and liver cancer, are becoming more common liver diseases due to unhealthy lifestyle and viral infections. Thus, increasing prevalence of liver diseases, increase demand for advanced technologies, and high focus on non-invasive test is driving the liver disease diagnostics market growth.

Early Detection and Prevention of Disease Anticipated to Market Growth

Early detection and prevention help to overcome liver diseases at early stage. By identifying liver condition at early stage, healthcare providers give advanced disease progress to improve patient’s outcome. Prevention of disease aimed to identify risk factors, utilizing non-invasive diagnostic tools, and promoting lifestyle changes also give preventive measure such as treatment, and vaccination at early stage.

• For instance, in November 2021, Philips Launched ultrasound imagining tools with advanced features for radiology to increase diagnostic confidence and workflow efficiency. The new system received approval from the U.S. Food and Drug Administration (FDA) for their new Liver Fat Quantification tools of ultrasound systems known as EPIQ Elite and Affiniti. The advanced diagnostic technique used for early detection of liver disease on the ultrasound systems known as, EPIQ Elite. This system enable patients to adopt lifestyle changes at early stage after detection of disorder to prevent liver disease.

Restraints:

High Cost of Equipment Disturb the Target Market Growth

The high cost of healthcare facilities, diagnostics tools, and shortage of skilled professionals to operate advanced diagnostic tools is expected to disrupt target market growth. In areas with limited sources, do not access the advanced liver diagnostics test due to high cost of equipment.

• Counterbalance Statements:  Invest in automation technologies to improve efficiency of tools and reduce labor costs, utilize maintenance software to identify potential issues before they occur. Develop cost-benefit plans before purchasing new equipment and track expenses to identify cost-saving areas.

Opportunities & Market Trends:

Integration of AI in Diagnostics Tool is projected to drive the Market Growth

Integration of AI in liver disease diagnosis is transforming the detection, assessment, and monitoring process in liver disease. AI algorithms contain complex datasets that help to identify diagnostic pattern and provide decision support. AI help to identify liver abnormalities, such as early stage metabolic-associated steatosis liver disease (MASLD), and hepatitis, by predicting individuals developed liver disease risk. AI can analyze large scale clinical and imaging data from electronic health records (EHRs), biomarkers, and medical imaging help physicians to identify liver diseases at an early and treatable stage, further enhancing the market expansion. 

• For instance, according to an article published by American Association in November 2024, the study was scheduled at The Liver Meeting, hosted by the American Association for the Study of Liver Diseases. Researchers used an AI algorithm to analyze imaging ?ndings in electronic health records from three sites within the University of Washington Medical System to identify patients for metabolic dysfunction-associated steatotic liver disease (MASLD). This study represents the use of artificial intelligence to improve the early detection of liver disease and AI powered tools help to improve healthcare systems and patient outcomes in MASLD diseases.

The liver disease diagnostics market is segmented into diagnostic technique, disease type, end-user, and region.

Diagnostic Technique:

By diagnostic techniques the target market is categorized into Imaging (electrography, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) scanner), blood test [(fragmentomics, liver function test, antibody test and others) genetic test] are the diagnostic techniques divided for the liver disease diagnostics market. The imaging segment hold the largest liver disease diagnostics market share due to non-invasive test and ability to provide visualizing of liver anatomy. Imaging techniques allow healthcare providers to detect liver tumors, assess liver damage and monitor disease progression by improving sensitivity, specificity, and accuracy of diagnosis, resulting to the market growth.

• For instance, in August 2024, Professor of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King’s College London, conducted a research to develop new Magnetic Resonance Elastography (MRE) technique based on Magnetic resonance Imaging (MRI) that uses low-frequency mechanical waves. This new medical imaging technology enable non-invasive detection of liver abnormalities. This MRE technology aimed with high efficiency and accuracy detection for metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis.

Disease Type:

By disease type, the market is divided into hepatitis, fatty liver disease, liver cancer, non-alcoholic fatty liver disease, alcoholic fatty liver disease, and others. The non-alcoholic fatty liver disease (NAFLD) plays dominate role in target market, due to rising prevalence in obesity, diabetes and metabolic syndrome. The increasing awareness of NAFLD in healthcare professionals and patients, raises the demand for effective diagnostic tools and non-invasive methods, such as imaging technology, biomarker tests, resulting to drive liver disease diagnostics market share.

• For instance, in June 2022, SRL Diagnostics launched Fatty Liver Index, a first line diagnostic test for non-alcoholic fatty live disease. The Fatty Liver Index is an algorithm that based on various parameters such as, gamma-glutamyl-transferase, triglycerides test, weight, height, body mass index for the prediction of NAFLD. This algorithm indicated liver disease diagnostics in non-invasive, accurate, and accessible test, which aligns with need for early and affordable diagnostic solution.

End-User:

Liver disease diagnostics market by end-user divided into hospitals, specialty clinics, diagnostic centers, and others. The hospitals play dominate role in target market due to availability of advanced diagnostics testing devices and high-quality patient care for early detection.

Region:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This region is dominating the market and is accounted for 36.7% share in 2024, driven by the increasing prevalence of liver cancer, such as hepatitis and non-alcoholic fatty liver diseases. The increasing demand for advanced diagnostic tools for enhancing early detection and patient outcomes, driving the market expansion in the region.

• For instance, in In January 2022, Siemens Healthineers launched Enhanced Liver Fibrosis (ELF) test in the U.S. The ELF test was available through collaboration with LabCorp and Quest Diagnostics, to providing access across the country. The ELF test was the first and only prognostic blood test granted DE Novo marketing authorization to assess disease progression in non-alcoholic steatohepatitis (NASH).

Asia Pacific: This region is the fastest growing region of target market due to the rising number of liver cancer, hepatitis B and hepatitis C, growing health awareness, and expanding healthcare infrastructure in countries such as China, India and other Asian regions.

Liver Disease Diagnostics Market Report Scope:

Segmentation:

By Diagnostic Technique:

• Imaging
  • Electrography
  • Ultrasound Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT) Scanner
  • Others
• Blood Test
  • Fragmentomics
  • Liver Function Test
  • Antibody Test
• Genetic Test

By Disease Type:

• Hepatitis
• Fatty Liver Disease
• Liver Cancer
• Non-Alcoholic Fatty Liver Disease
• Alcoholic Fatty Liver Disease

By End-User:

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the liver disease diagnostics market include Abbott, Boston Scientific Corporation, Thermo Fisher Scientific Inc. and other companies are holding significant positions in target market. The major companies are adopting strategies, such as new diagnostic technique launch, partnerships, agreement, higher investments, and collaboration with other organizations to expand their product portfolio.

Liver Disease Diagnostics Market Companies:

• Abbott
• Boston Scientific Corporation
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• HORIBA
• Perspectum
• FUJIFILM Corporation
• Laboratory Corporation of America Holdings
• Agilus Diagnostics
• Siemens
• Echosens
• Cosara
• Owlstone Medical Ltd
• BIOMÉRIEUX
• Bio-Rad Laboratories, Inc

View a Additional List of Companies in Liver Disease Diagnostics Market

• In April 2024, Apollo Hospitals launched the Fatty Liver Clinic at the Liver Disease and Transplantation Institute, Chennai with cutting-edge diagnostic tools and new pharmacological treatment. Apollo Hospitals, launched FibroScan Expert 630 diagnostic tool to revolutionize liver care and tackle non-alcoholic fatty liver disease. This advanced equipment, enables spleen stiffness measurement, ultrasound guidance system, and precise risk stratification for advanced chronic liver disease patients to optimized patient care.
• In May 2021, GENFIT launched NASHnext, a novel, non-invasive diagnostic test for non-alcoholic steatohepatitis (NASH), aimed to improve the lives of patients from metabolic and liver diseases. The NASHnext is a diagnostic technology that uses a novel, blood-based molecular biomarker test to identify NASH and fibrosis. The increasing prevalence of NASH disorder aimed to focus NASHnext diagnostic tool on target population for testing.

Analyst View:

The liver disease is increasing global health concerns, which is driven by the rising prevalence of liver diseases, such as hepatitis, non-alcoholic fatty liver disorder, liver cancer and cirrhosis, and technological innovations. To overcome these diseases, there has been increase in the awareness and rising demand for advanced diagnostics tools that focus on early detection and personalized healthcare, further propelling the market expansion.

More Related Reports

Foot and Mouth Disease Vaccine Market
Chronic Kidney Disease Drug Market
Liver Disease Diagnostics Market
Complex Disease Treatment Market
Liver Disease Treatment Market